Condition
Epstein-Barr Virus (EBV) Infection
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Recruiting2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06789159Phase 1Recruiting
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
NCT07133776Phase 1Not Yet RecruitingPrimary
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
NCT05127980RecruitingPrimary
Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection
Showing all 3 trials